4CPS-300 Effectiveness and safety of cemiplimab in squamous cell carcinoma of the skin in a third level hospital

Background and importanceSquamous cell carcinoma (SCC) is the second most common skin cancer. This type of cancer is most often found in areas which have been exposed to sunlight, such as the neck, head and arms, although it can occur anywhere on the body. The high prevalence and the scarcity of tre...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2021-03, Vol.28 (Suppl 1), p.A65-A65
Main Authors: Tejedor Tejada, E, Nieto Guindo, P, Verdejo Reche, F
Format: Article
Language:English
Subjects:
Cancer
Conflicts of interest
Immunotherapy
Monoclonal antibodies
Skin cancer
Squamous cell carcinoma
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and importanceSquamous cell carcinoma (SCC) is the second most common skin cancer. This type of cancer is most often found in areas which have been exposed to sunlight, such as the neck, head and arms, although it can occur anywhere on the body. The high prevalence and the scarcity of treatments make new treatments necessary.Aim and objectivesTo assess the efficacy and safety of cemiplimab in the treatment of squamous cell carcinoma.Material and methodsThis was a retrospective observational study from January to August 2020 (8 months). The following variables were collected: sex, age, race, previous treatment, area, size, duration until response and stage. Effectiveness was measured by means of the Breslow index, Clark level and images from computerised axial tomography (TAC). Safety was assessed by the incidence of adverse drug reactions.ResultsOutcomes were measured for seven patients (all men), with a mean age of 76.8 years and of Caucasian race. Previous treatments were: radiotherapy (50%) and surgery (50%). The average size of the carcinoma was 2.45 cm and stages II (57.2%), III (28.52%) and IV (14.28%). In terms of effectiveness, the Breslow index and Clark levels decreased by 57.14% and there was an improvement in CT images and in symptoms. In terms of safety, the appearance of diarrhoea in one patient was noteworthy.Conclusion and relevanceAccording to our results, it is possible to consider cemiplimab as an alternative treatment for squamous cell carcinoma. We believe that further studies are necessary to determine effectiveness.References and/or acknowledgementsMigden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med (Internet) 2018;379:341–51 (available from: http://www.nejm.org/doi/10.1056/NEJMoa1805131).Conflict of interestNo conflict of interest
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2021-eahpconf.132